Jennifer Layman Young
Payments from drug & device makers
Across 119 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$473
- GSK$270
- Novo Nordisk$211
- Merck$166
- Lilly USA, LLC$118
- Astellas Pharma US Inc$107
- plus $758 from 22 others
What the payments were for
- Food & beverage$2,102100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $473 |
| GSK | 16 | $270 |
| Novo Nordisk | 12 | $211 |
| Merck | 8 | $166 |
| Lilly USA, LLC | 7 | $118 |
| Astellas Pharma US Inc | 6 | $107 |
| Bayer | 6 | $98 |
| Boehringer Ingelheim | 5 | $80 |
| Novartis | 5 | $79 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $58 |
| Amgen | 4 | $53 |
| AstraZeneca | 3 | $45 |
| Collegium Pharmaceutical, Inc. | 2 | $37 |
| Mylan Specialty L.p. | 2 | $36 |
| Corium, LLC | 2 | $35 |
| Exact Sciences | 2 | $33 |
| BETA Bionics, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$2,102 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 29 | $38,241 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $36,413 |
| OzempicSemaglutide | 27 | $26,142 |
| EliquisApixaban | 13 | $20,665 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 14 | $2,287 |
| Pregabalin | 22 | $2,089 |
| Aripiprazole | 16 | $1,772 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,661 |
| Atorvastatin Calcium | 124 | $1,611 |
| Amlodipine Besylate | 153 | $1,474 |
| Levothyroxine Sodium | 118 | $1,397 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $1,252 |
| Diclofenac Sodium | 44 | $1,091 |
| Duloxetine Hcl | 28 | $1,028 |
| Buspirone Hcl | 55 | $968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $118 | $38,24129 claims |
| GSKTrelegy Ellipta | $270 | $36,41334 claims |
| Novo NordiskOzempic | $211 | $26,14227 claims |
| PfizerEliquis | $16 | $20,66513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.
Other family in Niles
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.